ArticleCureus2026
Evaluating the Lack of Association Between Preoperative Hormone Replacement Therapy and Increased Venous Thromboembolism After Arthroscopic Orthopedic Surgery.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone replacement therapy (HRT) has been associated with increased venous thromboembolism (VTE) risk in select patient populations, raising concern regarding its perioperative safety in orthopedic surgery. However, the impact of preoperative HRT use on postoperative complications following common arthroscopic procedures remains poorly characterized.
methodsThe TriNetX Research Network was queried to identify adults aged 40-75 who underwent arthroscopy of the shoulder, elbow, hip, knee, or ankle. Patients with documented HRT use within three months prior to surgery were propensity-matched 1:1 to controls with no HRT use any time before or within three months of surgery. Exclusions included prior VTE events, coagulation disorders, active neoplasm, and kidney failure. Propensity matching accounted for age, sex, body mass index (BMI) (>30), diabetes, hypertension, hyperlipidemia, tobacco use, cardiovascular comorbidities, autoimmune disease, and procedure type. The primary outcome was 90-day VTE, defined as deep vein thrombosis (DVT) or pulmonary embolism (PE); secondary outcomes included hospital readmission, surgical site infection, and hemarthrosis.
resultsAfter propensity score matching, each cohort included 3,868 patients. Ninety-day VTE occurred in 0.7% of HRT patients vs. 1.0% of controls (risk ratio, 0.68; 95% confidence interval, 0.42-1.10; p = 0.14). DVT (0.6% vs. 0.9%, p = 0.15), PE (0.3% vs. 0.3%; p = 1.00), readmission (p = 1.00), infection (p = 0.54), and hemarthrosis (p = 1.00) rates were also similar between the groups.
conclusionIn this large, multicenter, propensity-matched cohort, preoperative HRT was not associated with a statistically significant increase in 90-day VTE or other postoperative complications following arthroscopic surgery. These findings should be interpreted as reassuring but hypothesis-generating evidence rather than definitive guidance regarding perioperative HRT management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.